BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36204882)

  • 1. Delayed biopsy following completion of transarterial chemoembolization in patients with hepatocellular carcinoma: Effects on pathological outcomes and its advantages.
    Zhi W; Hou J; Fan S; Han Y
    J Cancer Res Ther; 2022 Sep; 18(5):1346-1351. PubMed ID: 36204882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postbiopsy arterioportal fistula in patients with hepatocellular carcinoma: clinical significance in transarterial chemoembolization.
    Park HS; Lee SH; Kim YI; Lee JS; Lim MK; Park JW; Lee JH; Kim CM
    AJR Am J Roentgenol; 2006 Feb; 186(2):556-61. PubMed ID: 16423968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma.
    Tu J; Jia Z; Ying X; Zhang D; Li S; Tian F; Jiang G
    Medicine (Baltimore); 2016 Dec; 95(49):e5606. PubMed ID: 27930585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
    Chen ZX; Jian ZW; Wu XW; Wang JC; Peng JY; Lao XM
    Cancer Med; 2019 Sep; 8(11):5097-5107. PubMed ID: 31313476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization.
    Siramolpiwat S; Punjachaipornpon T; Pornthisarn B; Vilaichone RK; Chonprasertsuk S; Tangaroonsanti A; Bhanthumkomol P; Phumyen A; Yasiri A; Kaewmanee M
    Dig Dis Sci; 2019 Nov; 64(11):3337-3345. PubMed ID: 31073737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
    Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
    Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study.
    Wang Z; Ren Z; Chen Y; Hu J; Yang G; Yu L; Yang X; Huang A; Zhang X; Zhou S; Sun H; Wang Y; Ge N; Xu X; Tang Z; Lau W; Fan J; Wang J; Zhou J
    Clin Cancer Res; 2018 May; 24(9):2074-2081. PubMed ID: 29420221
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined Chemoembolization and Radiotherapy Versus Chemoembolization Alone for Hepatocellular Carcinoma Invading the Hepatic Vein or Inferior Vena Cava.
    Alrashidi I; Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Gwon DI; Ko HK
    Cardiovasc Intervent Radiol; 2021 Jul; 44(7):1060-1069. PubMed ID: 33745071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma.
    Ni JY; Liu SS; Xu LF; Sun HL; Chen YT
    World J Gastroenterol; 2013 Jun; 19(24):3872-82. PubMed ID: 23840128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Hepatic Artery Complications After Liver Transplantation in Patients Who Received Pretransplant Transarterial Chemoembolization Therapy: A Single-Center Experience.
    Selim M; Hohenwalter EJ; Rilling WS; Hong JC
    Transplant Proc; 2023 Sep; 55(7):1631-1637. PubMed ID: 37391331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.
    Park Y; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yeon JE; Byun KS; Kim HS; Kim JH; Kim SU
    BMC Cancer; 2019 Apr; 19(1):363. PubMed ID: 30991968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.